Cargando…

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hida, Toyoaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156204/ https://www.ncbi.nlm.nih.gov/pubmed/30249170 http://dx.doi.org/10.1177/1753466618801167

Ejemplares similares

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non‐small cell lung cancer
por: Hida, Toyoaki, et al.
Publicado: (2017)

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
por: Oya, Yuko, et al.
Publicado: (2017)

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2017)

Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study
por: Fujimoto, Nobukazu, et al.
Publicado: (2020)

Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer
por: Yamaguchi, Teppei, et al.
Publicado: (2017)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status
por: Katsura, Hideyuki, et al.
Publicado: (2019)

The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
por: Huang, Jiaxing, et al.
Publicado: (2016)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
por: Oya, Yuko, et al.
Publicado: (2020)

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
por: Akamatsu, Hiroaki, et al.
Publicado: (2018)

Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
por: Lim, Joline S. J., et al.
Publicado: (2016)

Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
por: Kanai, Osamu, et al.
Publicado: (2018)

Effect of antibiotic use on the efficacy of nivolumab in the treatment of advanced/metastatic non-small cell lung cancer: A meta-analysis
por: Huo, Geng-wei, et al.
Publicado: (2021)

Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer
por: Lv, Weize, et al.
Publicado: (2022)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
por: Blackhall, Fiona, et al.
Publicado: (2017)

Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date
por: Tella, Sri Harsha, et al.
Publicado: (2019)

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
por: Ang, Yvonne LE, et al.
Publicado: (2016)

Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer
por: Umehara, Kengo, et al.
Publicado: (2021)

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
por: Yamazaki, Naoya, et al.
Publicado: (2017)

The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials
por: Jin, Conghui, et al.
Publicado: (2016)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial
por: Kim, Hye Ryun, et al.
Publicado: (2023)

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
por: Kato, Terufumi, et al.
Publicado: (2015)

Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis
por: Hirashima, Tomonori, et al.
Publicado: (2019)

Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer
por: Dermarkarian, Christopher R., et al.
Publicado: (2020)

Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer
por: Nishio, Makoto, et al.
Publicado: (2020)

Five‐year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non‐small‐cell lung cancer
por: Kanda, Shintaro, et al.
Publicado: (2020)

Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma
por: Freeman, Morganna, et al.
Publicado: (2015)

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer
por: Sakaguchi, Tadashi, et al.
Publicado: (2020)

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies
por: Horinouchi, Hidehito, et al.
Publicado: (2019)

Five-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: pooled analysis of the ONO-4538-05 and ONO-4538-06 studies
por: Saka, Hideo, et al.
Publicado: (2020)

Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study
por: Aoki, Tomokazu, et al.
Publicado: (2021)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
por: Yamaguchi, Teppei, et al.
Publicado: (2019)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study
por: Iinuma, Koji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gugmeqiddpvuq6t39t1ke5rupt